| چکیده انگلیسی مقاله |
Background: Glioblastoma multiforme (GBM) is one of the most invasive types of brain cancer. LncRNAs can be considered a new prognostic and diagnostic biomarker in GBM. This study comprehensively explored the interaction of lncRNAs with mRNAs in the TCGA database and proposed a novel promising biomarker with favorable diagnostic and prognostic values. Methods: The public data of RNA-seq and related clinical data were downloaded from the TCGA database. Differential expression analysis was conducted in R. GO and KEGG signaling pathways were used for enrichment. The STRING database was used for PPI analysis. CE-network was constructed by STAR database. Kaplan-Meier survival analysis and ROC curve analysis to indicate the biomarkers' diagnostic and prognostic values. Results: Differentially expressed data illustrated that 4428 mRNAs were differentially expressed in GBM. The GO and KEGG pathway analysis showed that the differentially expressed mRNAs were enriched in critical biological processes. The PPI showed that WEE1, BARD1, and CDK6 were the important PPI hubs. The ceRNA network data demonstrated critical lncRNAs. The data revealed that the lncRNA CRNDE, LINC00957, AC072061.1, AC068888.1, and DBH-AS1 are potential diagnostic prognostic biomarkers in the GBM patients. Conclusion: Altogether, we demonstrated lncRNA, and mRNA interaction and mentioned regulatory networks, considered a therapeutic option in GBM. In addition, we proposed potential diagnostic and prognostic biomarkers for the patients. |
| نویسندگان مقاله |
| Arash Poursheikhani
1. Department of Genetics and Advanced Medical Technology, Faculty of Medicine, AJA University of Medical Sciences, Tehran, Iran 2. Legal Medicine Research Center, Legal Medicine Organization, Tehran, Iran
| Meysam Mosallaei
Student Research Committee, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran
| Mehrdad Nasrollahzadeh Sabet
Department of Laboratory Sciences, School of Allied Health Medicine, AJA University of Medical Sciences, Tehran, Iran
| Mohammad Foad Heidari
Department of Laboratory Sciences, School of Allied Health Medicine, AJA University of Medical Sciences, Tehran, Iran.
| Mohsen Rajaeinejad
AJA Cancer Epidemiology Research and Treatment Center (AJA‐ CERTC), AJA University of Medical Sciences, Tehran, Iran
| Mohsen Chamanara
1. Toxicology Research Center, AJA University of Medical Sciences, Tehran, Iran 2. Department of Pharmacology, School of Medicine, AJA University of Medical Sciences, Tehran, Iran
| Mojtaba Yousefi zoshk
1. Trauma Research Center, AJA University of Medical Sciences, Tehran, Iran 2. Department of Pediatrics, School of Medicine, AJA University of Medical Sciences, Tehran, Iran
| Peyman Aslani
1. Department of Parasitology and Mycology, Faculty of Medicine, AJA University of Medical Sciences, Tehran, Iran 2. Infectious Research Center, AJA University of Medical Sciences, Tehran, Iran
| Ebrahim Hazrati
Department of Anesthesiology and Critical Care, AJA University of Medical Sciences, Tehran, Iran
| Mojgan Mohammadimehr
Department of Laboratory Sciences, School of Allied Health Medicine, AJA University of Medical Sciences, Tehran, Iran
| Javad Behroozi
1. Department of Genetics and Advanced Medical Technology, Faculty of Medicine, AJA University of Medical Sciences, Tehran, Iran 2. Research Center for Cancer Screening and Epidemiology, AJA University of Medical Sciences, Tehran, Iran
|